Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
HOME > REGULATORY
REGULATORY
- Kamikawa Runs for LDP Presidency, Resolved to Empower Healthcare Realm
September 12, 2024
- Mounjaro to Keep Price after CEA as Lilly’s Appeal for Raise Nixed
September 12, 2024
- Antivirals Push Up Japan’s Drug Spending in FY2023: MHLW
September 12, 2024
- Ex-Minister Kato Joins Fray in LDP Race, Pledges Inflation-Linked Drug Prices
September 11, 2024
- MHLW Proposes Periodic Survey of Vaccine Prices in Japan
September 11, 2024
- Takaichi Vows to Bolster Japan’s Self-Sufficiency of Drugs, Vaccines in LDP Race
September 11, 2024
- Japan Extends Re-Examination Period for Entyvio, Zintus
September 11, 2024
- AMED Research Exploring Low-Cost Method to Analyze Nitrosamine Impurities
September 11, 2024
- First Drug Delisting in Simplified Process Slated for March-End 2026: MHLW
September 10, 2024
- Eisai COO Calls for LDP Collaboration in AD Diagnosis, Treatment
September 10, 2024
- MHLW to Accept English Dossiers from Foreign Makers
September 9, 2024
- MHLW Proposes Scope of Observational Research Subject to Clinical Trials Act
September 9, 2024
- MHLW Floats 3 Perspectives to Codify Rules for Drug Supply Management
September 9, 2024
- PMDA-Led Inspections Will Help Straighten Up Generic Makers: MHLW Councilor
September 6, 2024
- MOF Intent on Expanding Scope of Off-Year Revision in 2025: Budget Examiner
September 6, 2024
- Trodelvy Up for Japan Panel Review on Sept. 12, Meiji COVID Jab on Agenda Too
September 6, 2024
- Japan to Prepare Fact Sheets on RSV Vaccine, Antibody
September 5, 2024
- Japan Poised to Launch FIH Trial System in FY2029 to Attract Global Seeds
September 5, 2024
- Japan Healthcare Spend Hit Record High of 47 Trillion Yen in FY2023
September 4, 2024
- Japan’s HIV and AIDS Cases Up for First Time in 7 Years
September 4, 2024
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…